CASE REPORTS. Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia: case report and literature review . Fahmi Yousef Khan; Mohamed A.yassin . Department of Medicine of Hamad ...

FOSTER CITY, Calif., May 14, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel ...

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 1.3% in that time frame, underperforming the S&P 500.

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 1.3% in that time frame, underperforming the S&P 500. Will the recent ...

Review quarterly and annual revenue, net income, and cash flow for Mirum Pharmaceuticals Inc (MIRM:XNAS) stock through the last fiscal year.

Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC and Herrmann R (1996) Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae Nucleic Acids Res 24:4420-4449. Hsu T, ...

View the latest Mirum Pharmaceuticals Inc. (MIRM) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Review the current Mirum Pharmaceuticals Inc (MIRM:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MIRM is the best investment for you.